EUS-guided core liver biopsy sampling using a 22-gauge fork-tip needle: a prospective blinded trial for histologic and lipidomic evaluation in nonalcoholic fatty liver disease

Published:August 19, 2019DOI:https://doi.org/10.1016/j.gie.2019.08.006

      Background and Aims

      Diagnostic tools for nonalcoholic fatty liver disease (NAFLD) detection and prognostication are limited, with histology remaining the criterion standard. We evaluated the feasibility and safety of EUS-guided liver biopsy (EUS-LB) sampling in NAFLD staging.

      Methods

      In a prospective cohort of NAFLD patients with steatohepatitis and early liver fibrosis based on magnetic resonance elastography (MRE), EUS-LB sampling procedures were performed using a 22-gauge fork-tip core biopsy needle. Samples were evaluated by a blinded pathologist. Total aggregate sample length (TASL), number of complete portal triads, ability to calculate NAFLD activity score, ability to stage liver fibrosis, and ability to provide enough core liver tissue for lipidomics analysis were evaluated. Performance of EUS-LB sampling was compared with MRE.

      Results

      Forty-one EUS-LB samples were obtained. The median TASL was 2.4 cm (interquartile range, 2.00-2.75). The median number of complete portal triads per TASL was 26 (interquartile range, 7-62). Of the samples, 100% were adequate to convey NAFLD activity score and fibrosis stage. All samples provided enough core liver tissue to allow the application of lipidomics testing. A significant positive linear association between EUS-LB sampling–detected fibrosis and MRE-detected fibrosis was observed (r = .469, P < .005). Compared with MRE, EUS-LB sampling established early fibrosis in 13 cases that MRE classified as normal. EUS-LB sampling–related adverse events occurred in 7% and were restricted to postprocedural pain.

      Conclusions

      EUS-LB sampling is a viable technique for full NAFLD evaluation and may be superior to MRE in establishing the diagnosis of nonalcoholic steatohepatitis with early fibrosis. (Clinical trial registration number: NCT02880189.)

      Abbreviations:

      CPT (complete portal triad), EUS-LB (EUS-guided liver biopsy), FNB (fine-needle biopsy), MRE (magnetic resonance elastography), NAFLD (nonalcoholic fatty liver disease), NASH (nonalcoholic steatohepatitis), TASL (total aggregate sample length)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Gastrointestinal Endoscopy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Shah N.D.
        • Sasatomi E.
        • Baron T.H.
        Endoscopic ultrasound-guided parenchymal liver biopsy: single center experience of a new dedicated core needle.
        Clin Gastroenterol Hepatol. 2017; 15: 784-786
        • DeWitt J.
        • Cho C.-M.
        • Lin J.
        • et al.
        Comparison of EUS-guided tissue acquisition using two different 19-gauge core biopsy needles: a multicenter, prospective, randomized, and blinded study.
        Endosc Int Open. 2015; 3: E471-E478
        • DeWitt J.
        • McGreevy K.
        • Cummings O.
        • et al.
        Initial experience with EUS-guided Tru-cut biopsy of benign liver disease.
        Gastrointest Endosc. 2009; 69: 535-542
        • Gleeson F.C.
        • Clayton A.C.
        • Zhang L.
        • et al.
        Adequacy of endoscopic ultrasound core needle biopsy specimen of nonmalignant hepatic parenchymal disease.
        Clin Gastroenterol Hepatol. 2008; 6: 1437-1440
        • Manning D.S.
        • Afdhal N.H.
        EUS-guided liver biopsy: a procedure looking for an indication.
        Gastrointest Endosc. 2009; 69: 543-545
        • Mathew A.
        EUS-guided routine liver biopsy in selected patients.
        Am J Gastroenterol. 2007; 102: 2354
        • Nakai Y.
        • Samarasena J.
        • Iwashita T.
        • et al.
        Autoimmune hepatitis diagnosed by endoscopic ultrasound-guided liver biopsy using a new 19-gauge histology needle.
        Endoscopy. 2012; 44: E67-E68
        • Sey M.S.L.
        • Al-Haddad M.
        • Imperiale T.F.
        • et al.
        EUS-guided liver biopsy for parenchymal disease: a comparison of diagnostic yield between two core biopsy needles.
        Gastrointest Endosc. 2016; 83: 347-352
        • Nieto J.
        • Khaleel H.
        • Challita Y.
        • et al.
        EUS-guided fine-needle core liver biopsy sampling using a novel 19-gauge needle with modified 1-pass, 1 actuation wet suction technique.
        Gastrointest Endosc. 2018; 87: 469-475
        • Saab S.
        • Phan J.
        • Jimenez M.A.
        • et al.
        Endoscopic ultrasound liver biopsies accurately predict the presence of fibrosis in patients with fatty liver.
        Clin Gastroenterol Hepatol. 2017; 15: 1477-1478
        • Ratziu V.
        • Charlotte F.
        • Heurtier A.
        • et al.
        Sampling variability of liver biopsy in nonalcoholic fatty liver disease.
        Gastroenterology. 2005; 128: 1898-1906
        • Puri P.
        • Baillie R.A.
        • Wiest M.M.
        • et al.
        A lipidomic analysis of nonalcoholic fatty liver disease.
        Hepatology. 2007; 46: 1081-1090
        • Rotman Y.
        • Sanyal A.J.
        Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease.
        Gut. 2017; 66: 180-190
        • Paglialunga S.
        • Dehn C.A.
        Clinical assessment of hepatic de novo lipogenesis in non-alcoholic fatty liver disease.
        Lipids Health Dis. 2016; 15: 159
        • Schulman A.R.
        • Thompson C.C.
        • Odze R.
        • et al.
        Optimizing EUS-guided liver biopsy sampling: comprehensive assessment of needle types and tissue acquisition techniques.
        Gastrointest Endosc. 2017; 85: 419-426
        • Kleiner D.E.
        • Brunt E.M.
        • Van Natta M.
        • et al.
        Design and validation of a histological scoring system for nonalcoholic fatty liver disease.
        Hepatology. 2005; 41: 1313-1321
        • Rockey D.C.
        • Caldwell S.H.
        • Goodman Z.D.
        • et al.
        Liver biopsy.
        Hepatology. 2009; 49: 1017-1044
        • Persson X.-M.T.
        • Blachnio-Zabielska A.U.
        • Jensen M.D.
        Rapid measurement of plasma free fatty acid concentration and isotopic enrichment using LC/MS.
        J Lipid Res. 2010; 51: 2761-2765
        • Bazerbachi F.
        • Haffar S.
        • Wang Z.
        • et al.
        Range of normal liver stiffness and factors associated with increased stiffness measurements in apparently healthy individuals.
        Clin Gastroenterol Hepatol. 2019; 17: 54-64
        • Hsu C.
        • Caussy C.
        • Imajo K.
        • et al.
        Magnetic resonance vs transient elastography analysis of patients with nonalcoholic fatty liver disease: a systematic review and pooled analysis of individual participants.
        Clin Gastroenterol Hepatol. 2019; 17: 630-637
        • Mohan B.P.
        • Shakhatreh M.
        • Garg R.
        • et al.
        Efficacy and safety of EUS-guided liver biopsy: a systematic review and meta-analysis.
        Gastrointest Endosc. 2019; 89: 238-246
        • Mok S.R.S.
        • Diehl D.L.
        • Johal A.S.
        • et al.
        Endoscopic ultrasound-guided biopsy in chronic liver disease: a randomized comparison of 19-G FNA and 22-G FNB needles.
        Endosc Int Open. 2019; 7: E62-E71
        • Burak K.W.
        • Angulo P.
        • Lindor K.D.
        Is there a role for liver biopsy in primary sclerosing cholangitis?.
        Am J Gastroenterol. 2003; 98: 1155